China-based anti-cancer therapies developer Immvira Co., Ltd has garnered as much as $58 million in its Series B round of financing. The round was led by Huagai Capital, a China market positioned private equity firm. Huagai closed its third healthcare fund at $434 million in April 2020, the company announced via WeChat on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
